1.1 	A bill for an act
1.2 	relating to higher education; specifying projects for which grant funds may be 
1.3 	used; requiring a report;amending Laws 2014, chapter 312, article 1, section 4, 
1.4 	subdivision 2.
1.5 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 	Section 1. Laws 2014, chapter 312, article 1, section 4, subdivision 2, is amended to read:

1.7	Subd. 2.Health Sciences Special
 				4,500,000
	
1.8 	(a) This appropriation is from the general fund 
1.9 	for the direct and indirect expenses of the 
1.10 	collaborative partnership between the 
1.11 	Univerity of Minnesota and the Mayo Clinic 
1.12 	for regenerative medicine research, clinical 
1.13 	translation, and commercialization. In addition 
1.14 	to representatives from the University of 
1.15 	Minnesota and the Mayo Clinic, the 
1.16 	collaborative partnership must include 
1.17 	representatives of private industry and others 
1.18 	with expertise in regenerative medicine 
1.19 	research, clinical translation, 
1.20 	commercialization, and medical venture 
1.21 	financing who are not affiliated with either 
1.22 	the University of Minnesota or the Mayo 
1.23 	Clinic.
2.1 	(b) By January 15 of each odd-numbered year 
2.2 	beginning in 2017, the partnership must 
2.3 	submit an independent financial audit to the 
2.4 	chairs and ranking minority members of the 
2.5 	committees of the house of representatives 
2.6 	and senate having jurisdiction over higher 
2.7 	education and economic development. The 
2.8 	audit must include the names of all recipients 
2.9 	of grants awarded by the partnership and their 
2.10 	affiliation, if any, with the University of 
2.11 	Minnesota or the Mayo Clinic.
2.12 	(c) The full amount of this appropriation is for 
2.13 	the partnership and may not be used by the 
2.14 	University of Minnesota for administrative or 
2.15 	monitoring expenses.
2.16 	(d) For fiscal year 2016 and thereafter, the 
2.17 	base for this program is $4,350,000.
2.18 	(e) All grants awarded with funding provided 
2.19 	by an appropriation to this program must be 
2.20 	for a regenerative medicine development 
2.21 	project, defined as any research, product 
2.22 	development, or commercial venture relating 
2.23 	to basic, preclinical, or clinical work to 
2.24 	produce a drug, biological or chemical 
2.25 	material, compound, or medical device 
2.26 	designed to augment, repair, replace, or 
2.27 	regenerate organs and tissue that have been 
2.28 	damaged by disease, injury, aging, or other 
2.29 	biological processes.
2.30 	(f) In response to the January 2020 Office of 
2.31 	the Legislative Auditor's report analyzing the 
2.32 	Regenerative Medicine Minnesota (RMM) 
2.33 	internal controls and compliance with the law, 
2.34 	the RMM shall address each recommendation 
2.35 	in the report, and demonstrate how RMM is 
3.1 	addressing the underlying issue related to each 
3.2 	recommendation.